Clinical Utility of Electrical Impedance Spectroscopy

Focus of Study: Patients With Suspicion of Melanoma Clinical Trial

Official title:

Evaluation of the Clinical Utility of Electrical Impedance Spectroscopy in Normal Clinical Practice at Hospital Setting

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04161742
• Other study ID #: FG-001
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 2019
• Est. completion date: August 2020

Study information

• Verified date: November 2019
• Source: SciBase AB
• Contact: Laura Ferris, MD
• Phone: +1 412-647-4200
• Email: ferrlk[@]UPMC.EDU
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical study is to evaluate the clinical utility of the Nevisense in normal clinical practice, i.e. the potential effect of implementing Nevisense in clinical decision making (Human vs Human & Machine) based on Nevisense measurement at time of biopsy decision.

Description:

This is a multi-center, prospective, blinded clinical study designed to evaluate clinical utility of Nevisense in normal clinical practice, i.e. the potential effect of implementing Nevisense in clinical decision making (Human vs Human & Machine) based on Nevisense measurement after biopsy decision. The study enrollment will continue until minimum of 180 subjects are enrolled in the study. Up to 3 US university/hospital investigational sites will participate in this study. Biopsying clinician or the investigators from the clinical practices of physicians participating in the study will perform the patient and lesion assessment for biopsy as standard of care at the clinic.

Study subjects will be recruited from the clinical practices of physicians participating as investigators in this study. Biopsying clinicians provide their assessment to whether s/he would have sent the lesion(s) for biopsy had s/he known the EIS information beforehand . Thereafter an evaluation of the suspicious lesion with the Nevisense will be performed followed by a biopsy of the lesion. The biopsied lesion will be subjected to histological analysis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 180
• Est. completion date: August 2020
• Est. primary completion date: June 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• The lesion(s) meet criteria for Nevisense evaluation.

• Lesions that present with unclear clinical presentation to allow for clinical diagnosis of benign or minimally dysplastic nevus (nevi) -Thus, necessitating a biopsy.

• Lesions within Nevisense indication for use: Nevisense is indicated for use on cutaneous lesions with one or more clinical or historical characteristics of melanoma, when a dermatologist chooses to obtain additional information when considering biopsy. Nevisense should not be used on clinically obvious melanoma. The Nevisense result is one element of the overall clinical assessment. The output of Nevisense should be used in combination with clinical and historical signs of melanoma to obtain additional information prior to a decision to biopsy. Nevisense is indicated only for use on:

• primary skin lesions with a diameter between 2 mm and 20 mm;

• lesions that are accessible by the Nevisense probe;

• lesions where the skin is intact (i.e. non-ulcerated or non-bleeding lesions);

• lesions that do not contain a scar or fibrosis consistent with previous trauma;

• lesions not located in areas of psoriasis, eczema, acute sunburn or similar skin conditions;

• lesions not in hair-covered areas;

• lesions which do not contain foreign matter;

• lesions not on special anatomic sites (i.e. not for use on acral skin, genitalia, eyes, mucosal areas).

Exclusion Criteria:

• Subjects who fail to provide informed consent

• Study subjects with underlying medical disease which may alter ability to diagnose clinically or inhibit Nevisense from collecting data

Related Conditions & MeSH terms

• Focus of Study: Patients With Suspicion of Melanoma
• Melanoma

Intervention

Device:
• Nevisense
Nevisense measures electrical impedance of skin lesions and provides an output called the electrical impedance spectroscopy (EIS) score

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
SciBase AB

References & Publications (2)

Malvehy J, Hauschild A, Curiel-Lewandrowski C, Mohr P, Hofmann-Wellenhof R, Motley R, Berking C, Grossman D, Paoli J, Loquai C, Olah J, Reinhold U, Wenger H, Dirschka T, Davis S, Henderson C, Rabinovitz H, Welzel J, Schadendorf D, Birgersson U. Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. Br J Dermatol. 2014 Nov;171(5):1099-107. doi: 10.1111/bjd.13121. Epub 2014 Oct 19. — View Citation

Rocha L, Menzies SW, Lo S, Avramidis M, Khoury R, Jackett L, Guitera P. Analysis of an electrical impedance spectroscopy system in short-term digital dermoscopy imaging of melanocytic lesions. Br J Dermatol. 2017 Nov;177(5):1432-1438. doi: 10.1111/bjd.15595. Epub 2017 Oct 11. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number needed to biopsy	The primary study outcome is the number needed to biopsy to detect a single melanoma case.	1 day